BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 37021976)

  • 1. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer.
    Guo D; Ye L; Wu W; Yu X; Jin K
    Acta Biochim Biophys Sin (Shanghai); 2023 Apr; 55(6):923-937. PubMed ID: 37021976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic reprogramming of immune cells in pancreatic cancer progression.
    Xiang H; Yang R; Tu J; Xi Y; Yang S; Lv L; Zhai X; Zhu Y; Dong D; Tao X
    Biomed Pharmacother; 2023 Jan; 157():113992. PubMed ID: 36395610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of lipid metabolic reprogramming in tumor microenvironment.
    Yang K; Wang X; Song C; He Z; Wang R; Xu Y; Jiang G; Wan Y; Mei J; Mao W
    Theranostics; 2023; 13(6):1774-1808. PubMed ID: 37064872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming of lipid metabolism in the tumor microenvironment: a strategy for tumor immunotherapy.
    Wu Y; Pu X; Wang X; Xu M
    Lipids Health Dis; 2024 Feb; 23(1):35. PubMed ID: 38302980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more.
    Hao X; Ren Y; Feng M; Wang Q; Wang Y
    Biomed Pharmacother; 2021 Sep; 141():111798. PubMed ID: 34120068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Tumor Metabolic Reprogramming in Tumor Immunity.
    Zhang X; Song W; Gao Y; Zhang Y; Zhao Y; Hao S; Ni T
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
    Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
    BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTGES Expression Is Associated with Metabolic and Immune Reprogramming in Pancreatic Ductal Adenocarcinoma.
    Murthy D; Attri KS
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment.
    Yu W; Lei Q; Yang L; Qin G; Liu S; Wang D; Ping Y; Zhang Y
    J Hematol Oncol; 2021 Nov; 14(1):187. PubMed ID: 34742349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics.
    Jin HR; Wang J; Wang ZJ; Xi MJ; Xia BH; Deng K; Yang JL
    J Hematol Oncol; 2023 Sep; 16(1):103. PubMed ID: 37700339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy.
    Zhang M; Wei T; Zhang X; Guo D
    Front Immunol; 2022; 13():937406. PubMed ID: 36131916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
    Liu YH; Hu CM; Hsu YS; Lee WH
    Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.
    Andersen HB; Ialchina R; Pedersen SF; Czaplinska D
    Cancer Metastasis Rev; 2021 Dec; 40(4):1093-1114. PubMed ID: 34855109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
    Huang L; Xu H; Peng G
    Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral lipid metabolic reprogramming as a pro-tumoral regulator in the tumor milieu.
    Wang R; Hu Q; Wu Y; Guan N; Han X; Guan X
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188962. PubMed ID: 37541532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
    Agrawal R; Natarajan KN
    Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipid Metabolic Reprogramming and Metabolic Stress in Liver Cancer].
    Xu Z; Yuan KF
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):561-565. PubMed ID: 34323031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.